Minerva Surgical Stock (NASDAQ:UTRS)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$NaN

52W Range

- - $6.16

50D Avg

$0.01

200D Avg

$0.47

Market Cap

$106.54K

Avg Vol (3M)

$42.00

Beta

4.61

Div Yield

-

UTRS Company Profile


Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

Show More

Industry

Medical - Healthcare Information Services

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

174

IPO Date

Oct 22, 2021

Website

UTRS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 21
Warranty Service$100.00K

Fiscal year ends in Dec 22 | Currency in USD

UTRS Financial Summary


Dec 22Dec 21Dec 20
Revenue$50.29M$52.10M$37.77M
Operating Income$-30.90M$-29.14M$-15.39M
Net Income$-34.11M$-21.46M$-18.26M
EBITDA$-30.88M$-18.86M$-8.16M
Basic EPS$-23.68$-61.22$-17.91
Diluted EPS$-23.68$-61.22$-17.91

Fiscal year ends in Dec 22 | Currency in USD

Latest Earnings Call Transcripts


Q2 23Aug 07, 23 | 12:54 AM
Q1 23May 02, 23 | 10:23 PM
Q4 22Mar 21, 23 | 5:47 PM

Peer Comparison


TickerCompany
AKANAkanda Corp.
SQLSeqLL Inc.
RNAZTransCode Therapeutics, Inc.
HILSTharimmune, Inc.
DRMADermata Therapeutics, Inc.